ERAS
Erasca Inc

747
Mkt Cap
$4.54B
Volume
17.31M
52W High
$16.41
52W Low
$1.01
PE Ratio
-33.23
ERAS Fundamentals
Price
$14.60
Prev Close
$15.26
Open
$15.36
50D MA
$11.98
Beta
1.35
Avg. Volume
4.02M
EPS (Annual)
-$0.4393
P/B
12.76
Rev/Employee
$0.00
$825.81
Loading...
Loading...

Earnings Recap

Based on current operating plans, Erasca's cash, cash equivalents, and marketable securities, combined with net proceeds from the January 2026 offering, are expected to fund operations into the second half of 2028.

Bullish

Erasca focuses on RAS/MAPK pathway-driven cancers with promising clinical programs like ERAS-0015 and ERAS-4001, supported by a modality-agnostic pipeline and an experienced team.

Bearish

Erasca faces substantial operating losses and requires significant additional capital, while its unproven scientific approach and lengthy development process are challenged by intense competition and regulatory uncertainty.

Latest ERAS News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.